Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Lizza Hendriks(Maastricht University), Martin Reck(German Center for Lung Research), David Planchard(Université Paris-Saclay), Antonio Passaro(European Institute of Oncology), Jessica Menis(University of Verona), Benjamin Solomon(Peter MacCallum Cancer Centre), Egbert F. Smit(Dutch Cancer Society), Solange Peters(University Hospital of Lausanne), Tony Mok(Chinese University of Hong Kong), Ursula Nestle(University Medical Center Freiburg), Giulia Veronesi(Vita-Salute San Raffaele University), Keith M. Kerr(University of Aberdeen)
Cited by 782
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k